



Attorney Docket No.: 6517.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Henrik Bengtsson

Application No.: 10/679,642

Group Art Unit: To Be Assigned

Filed: October 6, 2003

Examiner: To Be Assigned

For: Needle Device Comprising A Plurality of Needles

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 01/93927
2. US Patent No. 4,226,235
3. US Patent No. 4,340,048
4. US Patent No. 4,552,561
5. US Patent No. 5,858,001
6. US Patent No. 6,280,148


7. US Patent No. 5,957,895
8. US Patent No. 5,527,288
9. US Patent No. 4,245,634
10. US Patent No. 5,482,473
11. US Patent No. 5,390,671
12. US Patent No. 5,391,950
13. US Patent No. 5,954,643
14. US Patent No. 5,568,806
15. EP 1 177 802 A1
16. Heller Adam, Annual Review Of BioMedical Engineering, (1999), Vol. 1, pages 153-175.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: February 17, 2004




Marc A. Began, Reg. No. 48,829  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**Use the following customer number for all correspondence regarding this application.**

**23650**

PATENT TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6517.200-US

Serial No. 10/679,642

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant **Henrik Bengtsson**

(Use several sheets if necessary)

Filing Date **October 6, 2003**Group **To Be Assigned**

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,226,235	10-7-80	Sarnoff et al.	128	218	
	4,340,048	7-20-82	Eckenhoff	128	213	
	4,552,561	11-12-85	Eckenhoff et al.	604	896	
	5,858,001	1-12-99	Tsals et al.	604	135	
	6,280,148 B1	8-28-01	Zengerle et al.	417	44.1	
	5,957,895	9-28-99	Sage et al.	604	181	
	5,527,288	6-18-96	Gross et al.	604	140	
	4,245,634	1-20-81	Albisser et al.	128	213	
	5,482,473	1-9-96	Lord et al.	439	67	
	5,390,671	2-21-95	Lord et al.	128	635	
	5,391,950	2-21-95	Krawczak	327	384	
	5,568,806	10-29-96	Cheney, et al.	128	635	
	5,954,643	9-21-99	VanAntwerp et al.	600	316	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	01/93927	12-13-01	WO				
	1 177 802 A1	2-6-02	EP				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Heller Adam, Annual Review Of BioMedical Engineering, (1999), Vol. 1, pages 153-175.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket No.: 6517.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Henrik Bengtsson

Serial No.: 10/679,642

Group Art Unit: To Be Assigned

Filed: October 6, 2003

Examiner: To Be Assigned

For: Needle Device Comprising A Plurality of Needles

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 17, 2004

Rashida Haji

(name of person mailing paper)

Rashida Haji

(signature of person mailing paper)